Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02337426 · ClinicalTrials.gov registry record · Phase 1
Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 1 study of Adult Giant Cell Glioblastoma and Adult Gliosarcoma, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02337426 is a Phase 1 study of Adult Giant Cell Glioblastoma and Adult Gliosarcoma that has completed, run by Virginia Commonwealth University. The registered enrollment target is 12 participants, below the 43-participant average among 12 other Adult Giant Cell Glioblastoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02337426, a Phase 1 study of Adult Giant Cell Glioblastoma and Adult Gliosarcoma, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase 1 trial studies the side effects and best dose of dimethyl fumarate when given together with temozolomide and radiation therapy(RT) in treating patients with newly diagnosed glioblastoma multiforme (GBM). Dimethyl fumarate may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving dimethyl fumarate with temozolomide and radiation therapy may work better in treating glioblastoma multiforme.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- DRUG Dimethyl Fumarate
Study Locations (1)
Virginia
- Virginia Commonwealth University/Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-02-13 |
| Est. Completion | 2017-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02337426
The ClinicalTrials.gov registry entry for NCT02337426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 12 other Adult Giant Cell Glioblastoma trials with a reported enrollment target (72% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Adult Giant Cell Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT02337426 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT02337426 about?
NCT02337426 is a clinical study titled "Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". This phase 1 trial studies the side effects and best dose of dimethyl fumarate when given together with temozolomide and radiation therapy(RT) in treating patients with newly diagnosed glioblastoma multiforme (GBM). Dimethyl fumarate may help radiation therapy work better by making tumor cells more ...
What is the current status of trial NCT02337426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-02-13. Estimated completion is 2017-11-09.
What conditions does trial NCT02337426 study?
This clinical trial studies the following conditions: Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Adult Brain Glioblastoma.
What interventions are being tested in trial NCT02337426?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), Dimethyl Fumarate (DRUG).
Who is sponsoring clinical trial NCT02337426?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02337426 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Giant Cell Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
COMPLETED · Phase 1
-
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
COMPLETED · Phase 1
-
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
COMPLETED · Phase 1
-
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.